What the FDA labels say about taking them together
Cholestyramine and prednisolone
Prednisolone's FDA label (Orapred Odt) of June 3, 2025 names cholestyramine in its drug interactions section; the cholestyramine label PlainMeds reads does not name prednisolone. The prednisolone label: “Cholestyramine: Cholestyramine may increase the clearance of corticosteroids.”
Check it at the source: the cholestyramine FDA label on DailyMed (effective August 20, 2026, AiPing Pharmaceutical, Inc.); the prednisolone FDA label on DailyMed (effective June 25, 2026, PAI Holdings, LLC dba PAI Pharma).
What does the cholestyramine label say about prednisolone?
Cholestyramine's label (effective August 20, 2026) does not name prednisolone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Cholestyramine), AiPing Pharmaceutical, Inc., effective August 20, 2026 (SPL set 214ea05f-de81-4026-9df9-4ce3820668ee), via openFDA; the full label on DailyMed
What does the prednisolone label say about cholestyramine?
Orapred Odt label (Advanz Pharma (US) Corp., June 3, 2025), drug interactionsCholestyramine: Cholestyramine may increase the clearance of corticosteroids.
Source: FDA drug label (Orapred Odt, NDA021959), Advanz Pharma (US) Corp., effective June 3, 2025 (SPL set 1e379543-c4cf-4e72-953b-db15b7f0c2a1), via openFDA
Source: FDA drug label (PrednisoLONE Sodium Phosphate), PAI Holdings, LLC dba PAI Pharma, effective June 25, 2026 (SPL set d1f937e7-fed5-4079-bd52-5d930b34ae9f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cholestyramine | Prednisolone | |
|---|---|---|
| Labeled for | High cholesterol | Anemia, Leukemia, lymphoma and myeloma, Multiple sclerosis, Osteoarthritis, Asthma, Allergies, Herpes and shingles, Crohn's disease and ulcerative colitis, Eczema (atopic dermatitis), Organ transplant rejection |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.834 per packet Cholestyramine packet | $4.72 per mL 1% eye drop |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once